Roche’s Fenebrutinib Raises the Bar in Multiple Sclerosis Treatment

For years, multiple sclerosis (MS) treatment has followed a trade-off:

• Oral drugs → convenient, but lower efficacy
• High-efficacy therapies → effective, but often injectable or complex

Roche may be closing that gap. New Phase III data suggest its investigational oral drug fenebrutinib could deliver high efficacy without compromising convenience.

The Headline: Relapses Cut by More Than Half

In two pivotal Phase III trials—FENhance 1 and 2—fenebrutinib was compared against teriflunomide in patients with relapsing multiple sclerosis.

The results were not subtle:

• 51.1% reduction in annualised relapse rate (ARR) (FENhance 1)
• 58.5% reduction in ARR (FENhance 2)
• Both results were highly statistically significant

Translated: Patients on fenebrutinib could experience one relapse every ~17 years, more than double the relapse-free time seen with teriflunomide. These findings were presented at the American Academy of Neurology Annual Meeting 2026.

Not Just Relapses: Strong MRI Outcomes

Fenebrutinib didn’t stop at clinical endpoints. It also delivered deep reductions in brain disease activity. Compared to teriflunomide:

• ~70–78% reduction in active inflammatory lesions (T1-Gd+)
• ~76–82% reduction in chronic lesion burden (T2 lesions)

This matters because MRI activity is a leading indicator of long-term disability progression.

The Bigger Signal: A New Kind of BTK Inhibitor

Fenebrutinib belongs to a growing class: Bruton’s tyrosine kinase (BTK) inhibitors. But it’s not a typical one. Key differentiators:

• Non-covalent and reversible binding
• Crosses the blood-brain barrier
• Targets both:
  • B cells (peripheral immune system)
  • Microglia (central nervous system)

This dual action is critical. Most MS drugs target inflammation in the bloodstream.
Fenebrutinib goes further, into the brain, where chronic damage happens.

Disability Progression: Promising, But Not Definitive

Secondary endpoints showed positive trends, though not statistically definitive.

• 20% risk reduction in disability progression (FENhance 1)
• 13% reduction (FENhance 2)

Stronger signals were seen in:

• Overall disability
• Upper limb function

Takeaway:The drug clearly reduces relapses and brain activity. Its impact on long-term disability is encouraging but still evolving.

Safety Profile: Comparable, With a Caveat

On the surface, safety looks similar to teriflunomide:

• Liver enzyme elevations: comparable across both arms
• Infection rates: similar
• Serious adverse events: broadly aligned

But there’s a catch:

• Higher number of deaths observed in the fenebrutinib arm

Causes varied:

• Infections
• Diabetes complications
• Accidents
• Suicide
• Unknown causes

No single pattern emerged—but regulators will scrutinize this closely.

Consistency Across MS Types

Fenebrutinib’s story doesn’t end with relapsing MS. In the Phase III FENtrepid trial, it showed:

• Non-inferiority to Ocrevus in primary progressive multiple sclerosis (PPMS)

That’s significant because:

• PPMS has very limited treatment options
• Ocrevus remains the only widely approved therapy

If approved, fenebrutinib could become a rare crossover therapy for both relapsing and progressive forms.

Why This Matters for the MS Market?

Let’s be blunt. Despite multiple therapies:

• ~30% of patients still rely on low-efficacy oral drugs
• Many avoid high-efficacy options due to administration burden or safety concerns

Fenebrutinib directly targets this gap:

• Oral convenience
• High efficacy
• Broad disease coverage

That combination is commercially—and clinically—powerful.

What Happens Next?

Roche plans to submit data from all three Phase III trials to regulators. Key watchpoints:

• Regulatory stance on safety signals (especially mortality imbalance)
• Positioning vs existing high-efficacy therapies
• Potential label across RMS and PPMS

Final Take

Fenebrutinib is not just another MS drug. It represents a shift:

• From peripheral-only targeting → CNS-penetrant therapies
• From efficacy vs convenience trade-offs → both in one drug

If regulators are convinced on safety, this could reshape the MS treatment landscape. If not, it becomes another reminder: In MS, efficacy alone is never enough.